CTOs on the Move

Y Prime

www.y-prime.com

 
The process that we follow for all projects is simple: we translate real-world experiences into expert advice. Whether this is through consulting or software applications, we align our entire organization to help you solve the specifics of challenges faced. When organizations engage with Y Prime, they have a dedicated support team that never changes. The people you work with from Day 1 will be there until completion of your project – no “knowledge transfers,” or redundant personnel required.  
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.y-prime.com
  • 263 Great Valley Parkway
    Malvern, PA USA 19355
  • Phone: 267.620.2000

Executives

Name Title Contact Details

Similar Companies

Hs Pharma

Hs Pharma is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Leading Pharma

Leading Pharma, LLC is a privately owned generic pharmaceutical company that purchases, licenses, develops, manufactures and distributes high-quality, safe and effective products to drugstore chains, distributors, wholesalers, mass merchandisers, government agencies and managed care accounts in the U.S. Our products are available in various dosage forms across many therapeutic areas under the Leading label.

Sleep Prescription

Sleep Prescription is a Rancho Santa Margarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fralex Therapeutics

Fralex Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Innovative Cellular Therapeutics

Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.